08:08 AM EDT, 05/09/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) , a clinical-stage company specializing in immunotherapy for oncology, on Thursday said it will start enrollment for a new GOBLET study pancreatic cancer cohort after receiving German regulatory and ethics approvals.

This cohort will evaluate Oncolytic's pelareorep in combination with modified folfirinox (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). It is supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), a program established to accelerate the development of new treatments for pancreatic cancer.

The GOBLET study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 12 centers in Germany.